Summary of colonoscopic studies evaluating prevalence and detection rates for serrated lesions
| Authors | Year | Country | Study type | n | Patient population | Colonoscopy type | Results Prevalence | Results Detection rate |
|---|---|---|---|---|---|---|---|---|
| Spring | 2006 | Australia | Prospective | 190 | All (except FAP, HNPCC, HPS) | M, CE | SL 40% HP 29% SSA 9% TSA 0.7% | |
| Hetzel | 2010 | USA | Retrospective | 7192 | Average-risk screening | HD | HP 28% SSA 1.4% | SSA-DR 0.6% |
| Gurudu | 2010 | USA | Retrospective | 21 238 | All | WL | SSA-DR 2.9% | |
| Freedman | 2011 | USA | Retrospective | 1486 | Average-risk screening (>45 years) or surveillance | WL | SSP 6.9% | HP-DR 26% SSP-DR 8% |
| Kahi | 2011 | USA | Retrospective | 6681 | Average-risk screening | WL | SL 36% PSP 11% | PSP-DR 13% |
| Rondagh | 2011 | The Netherlands | Prospective | 2309 | All (except any hereditary form of CRC, SPS) | HD, CE | SL-DR 13.3% High-risk SP*-DR 2.5% PSP-DR 3.8% | |
| Buda | 2012 | Italy | Prospective | 985 | Average-risk screening | HD | SP 40% HP 26.4% SSL 10.9% TSA 2.3% | SL-DR 7.3% HP-DR 4.5% SSL-DR 2.3% TSA-DR 0.5% |
| Leung | 2012 | China (Hong Kong) | Retrospective | 1282 | Average-risk screening | HD, NBI | SP-DR 21.4% SA-DR 0.9% PSP-DR 7.2% LSP-DR 2.3% | |
| Liang | 2012 | USA | Retrospective | 18 003 | All | Assumed WL (no details) | SL-DR 20.6% (screening only SL-DR 13.9%) | |
| Min | 2012 | South Korea | Retrospective | 926 | Average-risk screening (>45 years) | WL | SP 17.5% | SL-DR 11.9% PSP-DR 5.3% |
| Alvarez | 2013 | Spain | Prospective | 5059 | Average-risk screening (50–69 years) | Assumed WL (no details) | SL-DR 20.8% PSP-DR 6.5% LSP-DR 1.8% SSA+TSA-DR 2.6% | |
| Anderson | 2013 | USA | Retrospective | 9100 | Average-risk screening and surveillance (all >50 years, NB poor prep and incomplete colonoscopy excluded) | Assumed WL (no details) | SL-DR† 8% screening SL-DR† 10% surveillance | |
| Kumbhari | 2013 | Australia | Retrospective | 1000 | All | WL, NBI | SSA-DR 5.3% (7% in Caucasians vs 2% in Chinese) | |
| Lee | 2013 | South Korea | Retrospective | 1375 | Average-risk screening (>50 years) | HD | SL 11% PSP 2.7% | SL-DR 11.3% PSP-DR 3.1% High-risk PSP-DR‡ 0.5% |
| Raju | 2013 | USA | Retrospective | 342 | Average-risk screening (50–75 years) | WL§ | SL 11.3% | SL-DR 23% SSA+TSA-DR 11% |
| Hazewinkel | 2014 | The Netherlands | Prospective | 1426 | Average-risk screening (50–75 years) | WL | SL 41.8% HP 35.5% SSA 6.2% TSA <0.1% | SL-DR 27.2% HP-DR 23.8 PSP-DR 12.2% SSA-DR 4.8% TSA-DR 0.1% |
| Payne | 2014 | USA and Germany | Retrospective | 7215 | Average-risk screening (>50 years) | Assumed WL (no details) | SL¶ 6.1% | SL-DR 4% PSL-DR 2.8% |
*Dysplastic serrated polyps or large (≥6 mm) proximal non-dysplastic serrated polyps.
†HPs proximal to sigmoid colon plus all SSPs serrated adenomas.
‡Dysplastic PSP or large (<1 cm).
§Plus lesion-recognition training, cap-fitted colonoscopy, rigorous cleansing and intensive inspection.
¶SSA/P or HPs >1 cm in proximal colon.
CE, chromoendoscopy; CRC, colorectal cancer; FAP, familial adenomatous polyposis; HD, high definition; HNPCC, hereditary non-polyposis colorectal cancer; HP, hyperplastic polyp; LSP, large (>1 cm) serrated polyp; M, magnification; NBI, narrow band imaging; PSP, proximal serrated polyp; S/HPS, serrated/hyperplastic polyposis syndrome; SA, serrated adenoma; SP, serrated polyp; SPS, serrated polyposis syndrome; SSA, sessile serrated adenoma; SSL, sessile serrated lesion; SSP, sessile serrated polyp; TSA, traditional serrated adenoma; WL, standard white light.